Scheef W, Wolf-Gruber D
Arzneimittelforschung. 1985;35(1):75-7.
In a double-blind clinical trial the analgesic efficacy and safety of ethyl-N-(2-amino-6-[4-fluorophenyl-methylamino] pyridin-3-yl)carbamate (flupirtine, designated trademark: Katadolon) as 100-mg capsules were compared to pentazocine capsules 50 mg in 52 patients with severe to very severe cancer pain. The duration of treatment was up to one week, the daily dose up to 6 capsules. The analgesic effect was assessed by a 4-point verbal rating scale. In both drug groups was no difference between the baseline pain intensity. Moreover, also the dosage (number of capsules/day) was similar in both groups. Final evaluation demonstrated that flupirtine was significantly more effective than pentazocine in reducing pain. The incidence of side-effects was similar in both treatment groups, flupirtine, however, caused less intensive and less clinically relevant adverse reactions. In conclusion the results indicate that flupirtine is a potent and well tolerated analgesic in the treatment of cancer pain.
在一项双盲临床试验中，将52例中重度至极重度癌痛患者的乙基 - N - (2 - 氨基 - 6 - [4 - 氟苯基 - 甲基氨基]吡啶 - 3 - 基)氨基甲酸酯（氟吡汀，商品名：卡他多）100毫克胶囊的镇痛效果和安全性与50毫克喷他佐辛胶囊进行了比较。治疗持续时间最长为一周，每日剂量最多为6粒胶囊。通过4级言语评定量表评估镇痛效果。两个药物组的基线疼痛强度无差异。此外，两组的剂量（每日胶囊数）也相似。最终评估表明，氟吡汀在减轻疼痛方面比喷他佐辛显著更有效。两个治疗组的副作用发生率相似，然而，氟吡汀引起的不良反应强度较低且临床相关性较小。总之，结果表明氟吡汀是治疗癌痛的一种强效且耐受性良好的镇痛药。
